MwanzoZYME • NASDAQ
add
Zymeworks Inc
Bei iliyotangulia
$ 14.20
Bei za siku
$ 13.77 - $ 14.32
Bei za mwaka
$ 7.97 - $ 17.69
Thamani ya kampuni katika soko
995.30M USD
Wastani wa hisa zilizouzwa
elfu 535.82
Uwiano wa bei na mapato
-
Mgao wa faida
-
Ubadilishanaji wa msingi
NASDAQ
Kwenye habari
Fedha
Taarifa ya Mapato
Mapato
Mapato halisi
| (USD) | Sep 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato | 16.00M | -3.07% |
Matumizi ya uendeshaji wa biashara | 13.85M | -18.36% |
Mapato halisi | -29.85M | -4.05% |
Kiwango cha faida halisi | -186.56 | -7.34% |
Mapato kwa kila hisa | -0.39 | 4.88% |
EBITDA | -32.19M | -6.72% |
Asilimia ya kodi ya mapato | -0.76% | — |
Taarifa ya Hali ya Kifedha
Jumla ya mali
Jumla ya dhima
| (USD) | Sep 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Uwekezaji wa pesa taslimu na vipindi vifupi | 297.20M | 0.61% |
Jumla ya mali | 487.15M | -12.44% |
Jumla ya dhima | 120.17M | -8.97% |
Jumla ya hisa | 366.98M | — |
hisa zilizosalia | 68.88M | — |
Uwiano wa bei na thamani | 2.69 | — |
Faida inayotokana na mali | -17.05% | — |
Faida inayotokana mtaji | -21.02% | — |
Mtiririko wa pesa
Mabadiliko halisi ya pesa taslimu
| (USD) | Sep 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato halisi | -29.85M | -4.05% |
Pesa kutokana na shughuli | -5.88M | 86.23% |
Pesa kutokana na uwekezaji | 72.26M | 1,129.30% |
Pesa kutokana na ufadhili | -14.98M | -890.03% |
Mabadiliko halisi ya pesa taslimu | 51.39M | 207.59% |
Mtiririko huru wa pesa | 20.70M | 162.21% |
Kuhusu
Zymeworks Inc. is a publicly held biotechnology company based in Vancouver,
British Columbia, that develops protein therapeutics for the treatment of cancer as well as for autoimmune and inflammatory diseases. The products are based upon the company's molecular modeling software for optimizing protein structure. In 2014, Zymeworks raised $44 million across various funding rounds according to PitchBook, placing it among the top 10 HealthTech businesses in the world to raise the most capital that year. In May 2017, Zymeworks held an IPO on the Toronto Stock Exchange, raising $59 million. This was the largest Canadian biotech IPO in more than a decade. By alphabetical order, Zymeworks is the last company on the Toronto Stock Exchange.
In May 2019, Zymeworks announced that GSK has expanded its 2016 licensing and collaboration agreement for the research, development and commercialization of bispecific antibodies across multiple disease areas. The extended agreement has meant that GSK can have access to Zymeworks' heavy-light chain pairing technology, which enables the development of bispecific and multifunctional therapeutics. Wikipedia
Afisa Mkuu Mtendaji (CEO)
Ilianzishwa
2003
Makao Makuu
Tovuti
Wafanyakazi
294
